BCAB
Q3 2026 EPS Estimate
$-8.50
Aug 6, 2026 · Reports before open

Analyst Sentiment

Wall St. Consensus
Buy
9 analysts·Limited coverage
67
Score
6 Buy (67%)3 Hold (33%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
667%
Hold
333%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$250.00
+5866.6%
Consensus
$250.00
+5866.6%
Bull
$250.00
+5866.6%
12-Month Target Range9 analysts
$250.00$250.00$250.00
Current $4.19Consensus
Current Price
$4.19
Upside to Consensus
$245.81

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-81.73%
EPS
FY2028
Rev+1416.67%
EPS
FY2029
Rev+338.46%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029E
Revenue Avg$20M$4M$55M$239M
Low$20M$4M$55M$239M
High$20M$4M$55M$239M
EBITDA Avg$-4M$-719,999$-11M$-48M
Low$-4M$-719,999$-11M$-48M
High$-4M$-719,999$-11M$-48M
EBIT Avg$-4M$-719,999$-11M$-48M
Low$-4M$-719,999$-11M$-48M
High$-4M$-719,999$-11M$-48M
Net Income Avg$-54M$-69M$-53M$-56M
Low$-54M$-69M$-53M$-56M
High$-54M$-69M$-53M$-56M
EPS Avg$-46.00$-58.50$-45.00$-48.00
Low$-46.00$-58.50$-45.00$-48.00
High$-46.00$-58.50$-45.00$-48.00
Analysts (Rev / EPS)2 / 11 / 11 / 11 / 1
Quarterly
MetricQ3 2026Q4 2026
Revenue Avg
Low
High
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-11M$-11M
Low$-11M$-11M
High$-11M$-11M
EPS Avg$-7.00$-7.00
Low$-7.00$-7.00
High$-7.00$-7.00
Analysts (Rev / EPS) / 1 / 1

Earnings Surprises

Recent Analyst Actions

May 23, 2024JMP Securities
BioAtla price target lowered to $5 from $12 at JMP Securities
Target:$5.00
-95.6%from $114.00
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.